The legal dispute began on 19 July 2019, when Tobinco Pharmaceuticals Limited initiated a lawsuit against the FDA, alleging misuse of authority and seeking compensation for the damages incurred. A statement from TPL released on 11 August confirms this outcome. The controversy originated between September and December 2013, when Dr Opuni accused Tobinco Pharmaceuticals of importing counterfeit drugs. The FDA's actions included sealing Tobinco's warehouses nationwide, leading to significant reputational damage and financial losses due to product expirations. Additionally, the FDA's prohibition of Bliss GVS Pharma Limited, Tobinco's key business partner at the time, from exporting to Ghana resulted in further product confiscations.